Bronchogen & Chonluten

Where the substance class comes from

Behind the two lies a separate line of research. The Russian gerontologist Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology have been working since 1973 on very short peptides, each assigned to a tissue: one for the pineal gland, one for the thymus, one for the airways.

The school’s hypothesis is explicitly epigenetic: short peptides of 2 to 7 amino acids are said to enter the cell nucleus and nucleolus, interact there with DNA and histones and influence the reading of genes, including their methylation status. That is how a 2021 review by the group describes it: a hypothesis with laboratory findings, not a chain of effects confirmed in humans.

Chonluten: the calmer

Chonluten is a tripeptide of glutamic acid, aspartic acid and glycine, also listed as EDG or T-34. It is assigned to the airway mucosa and to the regulation of inflammation there.

The most concrete finding comes from a 2022 cell study in which Khavinson was involved. Human monocytes of the THP-1 line were stimulated with bacterial lipopolysaccharide. Chonluten inhibited the release of TNF, all 5 peptides tested lowered TNF and interleukin-6 in differentiated cells, and the treated cells adhered less to activated endothelium.

Bronchogen: the builder

Bronchogen is a tetrapeptide of alanine, glutamic acid, aspartic acid and leucine, written in the papers as AEDL or ADEL. It is credited with regeneration: ciliated epithelium, mucus layer, surfactant.

On this there are two papers in rats in which damage modeled on chronic obstructive pulmonary disease was induced with nitrogen dioxide over 60 days. After one month of treatment, the typical signs of remodeling had receded, including goblet cell hyperplasia, squamous metaplasia and emphysema, and ciliated cells had been restored. Secretory immunoglobulin A and surfactant protein B rose measurably, and the cell picture and cytokine profile in the bronchial secretions normalized.

A third paper from 2014 studied the peptide in cultures of human bronchial epithelium at passages 1, 7 and 14. It influenced proteins such as Ki67 and Mcl-1 and the reading of differentiation genes, most strongly in the aged cultures. Using 3 physical methods, the authors showed direct binding to DNA in the major groove.

Why the duo is offered as a stack

The rationale is theoretical: Chonluten calms the irritated tissue, Bronchogen rebuilds it. No investigation of the combination exists; the evidence applies to each substance individually, and even then only in cell culture and animals.

Both are offered as capsules or as drops under the tongue, which is unusual for peptides. The reason lies in their shortness: for ultrashort peptides, transport via the peptide transporters of the intestinal mucosa and via amino acid transporters has been made plausible computationally and in the lab. Whether an effective amount reaches lung tissue in humans after swallowing has not been shown by this.

Why the lungs are a serious longevity topic

Regardless of the peptides, the organ is worth a look. The Buffalo Health Study followed 554 men and 641 women aged 20 to 89 years over 29 years. Those in the lowest fifth of forced expiratory volume in one second had a mortality risk ratio of 2.24 in men and 1.81 in women compared with the highest fifth.

Lung function is thus one of the most stable predictors of life expectancy. That is exactly why it is remarkable how rarely the lungs feature in biohacking. What holds up here is unspectacular: not smoking, endurance training, indoor air quality, respiratory muscle training.

What users report

There are many reports from users: less coughing, fewer infections, easier breathing; popular after respiratory infections, among former smokers and among endurance athletes. These reports are not proof of efficacy, and their origin weakens them: they come predominantly from the commercial environment of the preparations and from publications of the developer group.

What the studies show

Kuzubova et al., Bulletin of Experimental Biology and Medicine 2015

Rats in which damage modeled on COPD had been induced with nitrogen dioxide over 60 days received Bronchogen for one month. Endpoints were histology of the bronchial epithelium and the lungs, secretory immunoglobulin A and the cytokine profile in the bronchial secretions. The signs of remodeling receded, ciliated cells were restored, and secretory immunoglobulin A rose. An animal model with tissue findings, not a clinical endpoint.

Titova et al., Rossijskij Fiziologiceskij Zurnal 2017

The same model setup, with a focus on inflammation and surfactant. Measured were the cell composition and cytokine-enzyme profile of the bronchial secretions as well as secretory immunoglobulin A and surfactant protein B. After treatment, neutrophilic inflammation was lower and both markers were higher. Also rats.

Avolio et al., International Journal of Molecular Sciences 2022

Human monocytes of the THP-1 line, stimulated with lipopolysaccharide, treated with five peptides of the Khavinson school, including Chonluten. Chonluten inhibited TNF release, all peptides lowered TNF and interleukin-6 in differentiated cells, and adhesion to activated endothelial cells decreased. A cell culture study with Khavinson as co-author.

Khavinson et al., Lung 2014

Cultures of human embryonic bronchial epithelium at passages 1, 7 and 14. The tetrapeptide changed the levels of Ki67, Mcl-1, p53, CD79 and NOS-3 and the reading of several differentiation genes, most strongly in aged cultures. In parallel, binding to DNA in the major groove was shown with three physical methods. A mechanistic finding without reference to disease.

Where the data stop

For neither of the two peptides is there a controlled study in humans with a clinical endpoint, and none is listed in the public trial registries. This leaves the obvious questions open: whether cough, sputum, exercise capacity or lung function values change measurably, whether this is possible at all after swallowing, and how much reaches the target tissue. A second point concerns the origin of the data. Almost all papers come from the same line of research, some with the developers as co-authors, and the Russian reports of use in chronic bronchitis and COPD are not published in a form that would make them verifiable by today’s standards. Independent replication is lacking. The epigenetic narrative also has a gap: that the tetrapeptide binds to DNA in a laboratory experiment and influences genes in cell cultures says nothing about whether the same happens in human lung tissue. Some of the work on this peptide even comes from plant research, on tobacco root cells.

Status, approval and legal

Neither Bronchogen nor Chonluten is approved as a medicine in Germany or the EU. As food supplements, synthetic short peptides would be novel foods and would need authorization under the EU Novel Food Regulation; no such authorization exists. They are traded as research products or as imported preparations, partly from Russia, where this class of substances has been sold for decades. In practice this means: no tested content, no assured sequence, no liability for use in humans. For peptides from such sources, the US Food and Drug Administration generally points to the risk of immune reactions due to aggregation and peptide-related impurities, and to the fact that characterizing the active substance is difficult. In competitive sports: an unapproved substance falls under group S0 of the World Anti-Doping Agency and is prohibited at all times.

Safety

Systematic safety data in humans do not exist. The class of substances is considered to have very few side effects, but this assessment comes from the same sources that also describe the effect and has not been independently verified. Specific contraindications can therefore not be given. The greater risk is a different one, and it does not lie in the substance: persistent cough, shortness of breath, coughing up blood, breathlessness on exertion or unintended weight loss are symptoms that should be checked by a doctor. They can be caused by asthma, COPD, heart disease, an infection or a tumor, and for all of these there are tested treatments. Anyone who tackles this on their own with an unapproved peptide from the gray market loses time. For asthma or COPD under treatment, the following also applies: do not replace or stop prescribed medication.

Sources

• Khavinson et al., Molecules 2021 — Peptide Regulation of Gene Expression, systematic review by the Khavinson school
• Avolio et al., International Journal of Molecular Sciences 2022 — Chonluten and other Khavinson peptides in human monocytes
• Khavinson et al., Lung 2014 — tetrapeptide ADEL, gene expression and DNA binding in bronchial epithelium
• Kuzubova et al., Bulletin of Experimental Biology and Medicine 2015 — Bronchogen in a rat model of obstructive lung damage
• Titova et al., Rossijskij Fiziologiceskij Zurnal 2017 — inflammation, secretory IgA and surfactant protein B in the same model
• Khavinson et al., International Journal of Molecular Sciences 2022 — transport of ultrashort peptides via POT and LAT transporters
• Schünemann et al., Chest 2000 — lung function as a long-term predictor of mortality, Buffalo Health Study
• Hailu et al., Cureus 2026 — unregulated peptide use, gray market and product quality
• FDA — Bulk Drug Substances: immunogenicity and impurities in peptides from compounding sources
• ClinicalTrials.gov — search for Bronchogen and Chonluten without a matching registered study